Key result
Translational readthrough-inducing compounds offer a promising therapeutic strategy for genetic diseases caused by nonsense mutations, though clinical application remains limited by drug toxicity and variable efficacy.
This review highlights the challenges of toxicity and bioavailability in using pharmaceutical compounds for translational readthrough of premature termination codons and discusses strategies to overcome them.
Answers are grounded in this paper and cite their sources.
Readthrough compounds remain investigational for nonsense mutations; leaves open clinical translation pending safer, more efficacious agents.
Premature termination codons (PTCs) in the coding regions of mRNA lead to the incorrect termination of translation and generation of non-functional, truncated proteins. Translational readthrough of PTCs induced by pharmaceutical compounds is a promising way of restoring functional protein expression and reducing disease symptoms, without affecting the genome or transcriptome of the patient. While in some cases proven effective, the clinical use of readthrough-inducing compounds is still associated with many risks and difficulties. This review focuses on problems directly associated with compounds used to stimulate PTC readthrough, such as their interactions with the cell and organism, their toxicity and bioavailability (cell permeability; tissue deposition etc.). Various strategies designed to overcome these problems are presented.
No takes yet. Share an insight, caveat, or question.
Dabrowski et al. (2018) conducted a review in Genetic diseases caused by nonsense mutations (premature termination codons). Translational readthrough-inducing compounds (e.g., aminoglycosides, PTC124) was evaluated. Translational readthrough-inducing compounds offer a promising therapeutic strategy for genetic diseases caused by nonsense mutations, though clinical application remains limited by drug toxicity and variable efficacy.
Synapse has enriched 10 related papers. Consider them for comparative context: